HAVN Life Sciences Inc.
HAVLF · OTC
4/30/2022 | 4/30/2021 | 4/30/2020 | |
|---|---|---|---|
| Market Cap | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | -$0 | $0 |
| % Margin | 32.4% | – | – |
| EBITDA | -$0 | -$0 | $0 |
| % Margin | -2,711.4% | – | – |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | -8,117.8% | – | – |
| EPS Diluted | -5.25 | -8.47 | -0.018 |
| % Growth | 38% | -46,438.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 |